Immune Pharmaceuticals Inc (fka IMNPQ)

[jloerke]

10 Nov 2016 10Q reflects:
Common stock, $0.0001 par value; authorized 225,000,000 shares; 112,691,362 and 32,434,942 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively

Series D Preferred Stock, net of discount, par value $0.0001, 12,000 shares authorized, 1,263 shares issued and 0 shares outstanding as of September 30, 2016 and 1,263 shares issued and 963 outstanding as of December 31, 2015

If they want to stay compliant with the NASDAQ, definitely r/s! now it's just a waiting game. Would be nice to have some positive results from their Phase 3 trials to get this above $1